Das Asmit, Sonar Swarup, Dhar Rajib, Subramaniyan Vetriselvan
Department of Oncology and Maxillofacial Pathology, Neuron Institute of Applied Research, Amravati, Maharashtra, India.
Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Subang Jaya, Selangor 47500, Malaysia.
Pathol Res Pract. 2025 May;269:155950. doi: 10.1016/j.prp.2025.155950. Epub 2025 Mar 29.
Melanoma, an aggressive form of skin cancer, presents significant therapeutic challenges due to its resistance to conventional treatments and propensity for metastasis. Exosomes, nanoscale vesicles secreted by a wide variety of cells, have emerged as promising tools for developing novel melanoma therapies. Exosome-based therapeutic approaches offer several advantages, including inherent biocompatibility, low immunogenicity, and the ability to cross biological barriers. This review explores the therapeutic potential of exosomes in melanoma treatment, focusing on their multifaceted roles in modulating tumor cell behavior, enhancing anti-tumor immune responses, and serving as targeted drug delivery vehicles. We discuss various strategies employed to engineer exosomes for enhanced therapeutic efficacy, including loading them with chemotherapeutic agents, small interfering RNAs (siRNAs), microRNAs (miRNAs), and immunomodulatory molecules. Additionally, we highlight the potential of exosomes derived from diverse sources to enhance anti-cancer effects. Furthermore, we address the challenges and future directions in translating exosome-based therapies from bench to bedside, emphasizing the need for standardized isolation and manufacturing protocols, as well as rigorous preclinical and clinical evaluations to unlock the full therapeutic potential of exosomes in the fight against melanoma.
黑色素瘤是一种侵袭性皮肤癌,由于其对传统治疗的耐药性和转移倾向,带来了重大的治疗挑战。外泌体是由多种细胞分泌的纳米级囊泡,已成为开发新型黑色素瘤治疗方法的有前景的工具。基于外泌体的治疗方法具有多种优势,包括固有的生物相容性、低免疫原性以及穿越生物屏障的能力。本综述探讨了外泌体在黑色素瘤治疗中的治疗潜力,重点关注它们在调节肿瘤细胞行为、增强抗肿瘤免疫反应以及作为靶向药物递送载体方面的多方面作用。我们讨论了为提高治疗效果而对外泌体进行工程改造所采用的各种策略,包括向外泌体中加载化疗药物、小干扰RNA(siRNA)、微小RNA(miRNA)和免疫调节分子。此外,我们强调了来自不同来源的外泌体增强抗癌效果的潜力。此外,我们还讨论了将基于外泌体的疗法从实验室转化到临床应用中所面临的挑战和未来方向,强调需要标准化的分离和生产方案,以及严格的临床前和临床评估,以释放外泌体在对抗黑色素瘤中的全部治疗潜力。